X4 Pharmaceuticals (XFOR) Other Non Operating Income (2017 - 2025)
X4 Pharmaceuticals (XFOR) reported Other Non Operating Income of -$676000.0 for Q3 2025, down 399.12% on a YoY basis from $226000.0 in Q3 2024, and down 125.59% quarter-over-quarter from $2.6 million in Q2 2025.
X4 Pharmaceuticals (XFOR) Other Non Operating Income (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Other Non Operating Income for 9 years, with the latest figure at -$676000.0 in Q3 2025.
- For the quarter ending Q3 2025, Other Non Operating Income fell 399.12% year-over-year to -$676000.0; the trailing twelve-month figure through Dec 2025 stood at $2.1 million (up 76.26% YoY), and the FY2025 full-year result was -$753000.0, down 139.06% from the prior year.
- Other Non Operating Income for Q3 2025 stood at -$676000.0, down from $2.6 million in the prior quarter.
- The five-year high for Other Non Operating Income was $25.2 million in Q3 2023, with the low at -$3.8 million in Q4 2022.
- Historically, Other Non Operating Income has averaged $1.3 million across 5 years, with a median of $105000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 495.95% — and 2023, when it jumped 5806.12%.
- X4 Pharmaceuticals' Other Non Operating Income stood at -$689000.0 in 2021, then plunged by 445.28% to -$3.8 million in 2022, then surged by 94.97% to -$189000.0 in 2023, then soared by 470.37% to $700000.0 in 2024, then plunged by 196.57% to -$676000.0 in 2025.
- The last three Other Non Operating Income figures came in at -$676000.0 (Q3 2025), $2.6 million (Q2 2025), and $105000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | X4 Pharmaceuticals | 166.63 Mn | 166.63 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -676,000.00 |
| Jun 30, 2025 | 2.64 Mn |
| Mar 31, 2025 | 105,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 144,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | -189,000.00 |
| Sep 30, 2023 | 25.16 Mn |
| Jun 30, 2023 | 202,000.00 |
| Mar 31, 2023 | 123,000.00 |
| Dec 31, 2022 | -3.76 Mn |
| Sep 30, 2022 | -441,000.00 |
| Jun 30, 2022 | -59,000.00 |
| Mar 31, 2022 | 60,000.00 |
| Dec 31, 2021 | -689,000.00 |
| Sep 30, 2021 | -74,000.00 |
| Jun 30, 2021 | 210,000.00 |
| Mar 31, 2021 | -31,000.00 |
| Dec 31, 2020 | -478,000.00 |